Shukla Ashutosh M, Archibald Lennox K, Wagle Shukla Aparna, Mehta Hiren J, Cherabuddi Kartikeya
North Florida South Georgia VHS, Gainesville, FL, USA.
Department of Medicine, University of Florida, Gainesville, FL, USA.
Drugs Context. 2020 Apr 28;9. doi: 10.7573/dic.2020-4-5. eCollection 2020.
Chloroquine and closely related structural analogs, employed initially for the treatment of malaria, are now gaining worldwide attention due to the rapidly spreading pandemic caused by severe acute respiratory syndrome-coronavirus-2, named coronavirus disease (COVID) of 2019 (COVID-19). Although much of this attention has a mechanistic basis, the hard efficacy data for chloroquine/hydroxychloroquine in the management of the clinical syndrome of COVID-19 have been limited thus far. This review aims to present the available and clinical data for the role of chloroquine/hydroxychloroquine in COVID-19 and attempts to put them into perspective, especially in relation to the different risks/benefits particular to each patient who may require treatment.
氯喹及其结构紧密相关的类似物最初用于治疗疟疾，如今，由于严重急性呼吸综合征冠状病毒2（即2019冠状病毒病，简称COVID-19）引发的全球大流行迅速蔓延，它们正受到全世界的关注。尽管这种关注大多有其机制基础，但到目前为止，氯喹/羟氯喹在治疗COVID-19临床综合征方面的确切疗效数据仍然有限。本综述旨在介绍氯喹/羟氯喹在COVID-19治疗中所起作用的现有临床数据，并尝试对这些数据进行客观分析，尤其是针对可能需要治疗的每位患者的不同风险/益处。
